Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on biophysical and biochemical surfactant properties
- 1 May 2002
- journal article
- clinical trial
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 19 (5) , 797-804
- https://doi.org/10.1183/09031936.02.00243302
Abstract
The purpose of the present study was to investigate the impact of bronchoscopic surfactant administration, on the biochemical and biophysical surfactant properties, in patients with severe and early acute respiratory distress syndrome (ARDS) and septic shock.A total number of 27 ARDS patients received 300–500 mg·kg·body·weight−1of a natural bovine surfactant extract (Alveofact®)viaa flexible bronchoscope. Bronchoalveolar lavages were performed 3 h prior to, and 15–18 h and 72 h after surfactant administration. A comparison to healthy volunteers, undergoing an identical lavage procedure, was made (control, n=12).Severe biophysical and biochemical surfactant abnormalities were encountered throughout in the ARDS patients. These included a massive alveolar protein load, a reduced percentage of large surfactant aggregates (LA), a loss of palmitoylated phosphatidylcholine species and a significant reduction of surfactant apoprotein (SP)-A, SP-B and SP-C in the LA fraction. Both minimum (γmin) and adsorption (γads) surface tension values (pulsating bubble surfactometer) were dramatically increased. Surfactant treatment resulted in a marked increase in the lavagable phospholipid (PL) pool, but predominance of the alveolar surfactant-inhibitory protein load was still encountered. Far-reaching or even complete normalization of the PL profile, the LA fraction and its SP-B and SP-C (but not SP-A) content as well as the fatty acid composition of the phosphatidylcholine class was noted. Surface tension lowering properties (γmin and γads) significantly improved, but were still not fully normalized.Bronchoscopic administration of large quantities of natural bovine surfactant in severe acute respiratory distress syndrome causes far-reaching restoration of biochemical surfactant properties and significant improvement, however not full normalization, of biophysical surfactant function.Keywords
This publication has 30 references indexed in Scilit:
- Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamicsEuropean Respiratory Journal, 2002
- Alteration of Fatty Acid Profiles in Different Pulmonary Surfactant Phospholipids in Acute Respiratory Distress Syndrome and Severe PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Bovine surfactant therapy for patients with acute respiratory distress syndrome.American Journal of Respiratory and Critical Care Medicine, 1997
- Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis.American Journal of Respiratory and Critical Care Medicine, 1996
- Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema.American Journal of Respiratory and Critical Care Medicine, 1996
- Acute Effects of a Single Dose of Porcine Surfactant on Patients With the Adult Respiratory Distress SyndromeChest, 1994
- Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome.Journal of Clinical Investigation, 1991
- A multicenter randomized controlled clinical trial of bovine surfactant for prevention of respiratory distress syndromeLung, 1990
- Surfactant Abnormalities in Patients with Respiratory Failure after Multiple TraumaAmerican Review of Respiratory Disease, 1989
- Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol.Journal of Clinical Investigation, 1982